Fig. 2From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activityModel validation: Survival curves estimated from an analytical model comparing RA patients aged 45Â years at diagnosis with the general population aged 45Â yearsBack to article page